Schedule 13G ownership disclosure
Spyre Therapeutics Inc
Security class unavailable · CUSIP: 00773J202
Event date: 2023-12-31
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 2,125,597
- Percent of class
- 5.9000%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000902664-24-001596
- Form type
- SC 13G
- Filer
- Avoro Capital Advisors LLC
- CIK
- CIK 1633313
- Filed
- Feb 14, 2024
- Reporting period
- Dec 31, 2023
- Description
- Schedule 13G beneficial ownership